PRECIGEN, INC. Interest Payable
PRECIGEN, INC. (PGEN) had Interest Payable of $127.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Balance Sheet › Liabilities
us-gaap:InterestPayableCurrentAndNoncurrent · last filed 2024-03-19
- 2023-03-31: Interest Payable $127.00K.
- 2022-12-31: Interest Payable $759.00K.
- 2022-09-30: Interest Payable $721.00K.
- 2022-06-30: Interest Payable $3.50M.
| Period end | Interest Payable |
|---|---|
| 2023-03-31 | $127.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $759.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $721.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.50M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.75M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.50M 10-K · filed 2022-03-01 |
| 2021-09-30 | $1.75M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $3.50M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.75M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $3.50M 10-K · filed 2021-03-01 |
| 2020-09-30 | $1.75M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $3.50M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.75M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.50M 10-K · filed 2020-03-02 |
| 2019-09-30 | $1.75M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |